Title:
【発明の名称】T-細胞抗原、並びにT-細胞介在状態の診断及び処理へのそれらの使用
Document Type and Number:
Japanese Patent JPH09509053
Kind Code:
A
Abstract:
The OX-40 antigen is characterized and claimed together with variants and derivatives thereof. Also described are binding agents for the antigen and the use of these in diagnosis and therapy. Examples of such use include a method for the selective depletion of activated CD4+ T-cells in vivo by using immunotoxins comprising an OX-40 antibody conjugated to a toxic molecule (such as Ricin-A chain). The administration of these specific immunotoxins is used therapeutically to deplete autoimmune reactive CD4+ T-cells which have been implicated in diseases including Multiple Sclerosis, Rheumatoid Arthritis, Sarcoidosis, and Autoimmune Uveitis as well as inflammatory bowel disease and graft-versus-host disease. This type of therapy is also beneficial for eradicating CD4+ T-cell lymphomas and alloreactive CD4+ T-cells involved with a transplantation reaction. The use of the human form of the OX-40 antibody will also help in the early diagnosis of all the diseases mentioned above.
Inventors:
Weinberg, Andrew Dale
Banden Bourke, Arthur Allen
Banden Bourke, Arthur Allen
Application Number:
JP52047495A
Publication Date:
September 16, 1997
Filing Date:
February 06, 1995
Export Citation:
Assignee:
Weinberg, Andrew Dale
Banden Bourke, Arthur Allen
Banden Bourke, Arthur Allen
International Classes:
G01N33/53; A61K39/395; A61K47/48; A61K49/00; A61K51/00; A61K51/10; A61P29/00; A61P35/02; A61P37/00; A61P37/06; C07H21/04; C07K14/705; C07K14/725; C07K14/73; C07K16/28; C12N15/09; C12P21/02; C12P21/08; G01N33/577; A61K38/00; C12R1/91; (IPC1-7): C12N15/09; A61K39/395; A61K47/48; A61K51/00; C07H21/04; C07K14/73; C07K16/28; G01N33/53; G01N33/577
Attorney, Agent or Firm:
Takashi Ishida (3 others)